Drugs against Marek's disease virus and application of RA190 or glycyrrhizic acid and their combined use in drug preparation

The inhibition of MDV049 protease and UL23 thymidine kinase activity by RA190 and glycyrrhizic acid alone or in combination, solving the problems of MDV replication and virility enhancement in the prior art, and effectively inhibiting the replication and tumor of Marek's disease virus at low doses Growth improves vaccine defense effect.

CN118078824BActive Publication Date: 2024-11-08JILIN UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410247712.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-03-05
Publication Date
2024-11-08
Estimated Expiration
2044-03-05

AI Technical Summary

Technical Problem

The prior art cannot effectively inhibit the replication and virility of Marek's disease virus (MDV) in chicken cells, causing the chickens to become a new source of infection after vaccine immunization and promote virility enhancement.

Method used

Using RA190 and/or glycyrrhizic acid alone or in combination, by inhibiting the MDV-encoded MDV049 protease and UL23 thymidine kinase activity, it significantly inhibits viral replication and effectively prevents the occurrence of Marek's disease in a safe dose.

Benefits of technology

RA190 and glycyrrhizic acid can significantly inhibit the replication of MDV and tumor growth in cellular and animal models, improve vaccine defense effects, reduce virility enhancement, and have no toxic side effects at low doses, which has good economic value and research significance.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118078824B_ABST
    Figure CN118078824B_ABST
Patent Text Reader

Abstract

The present invention provides a drug for inhibiting Marek's disease virus, including RA190 and / or glycyrrhizic acid alone or in combination, wherein RA190 is an MDV049 protease inhibitor and glycyrrhizic acid is a UL23 thymidine kinase inhibitor. The present invention also provides the use of RA190 or glycyrrhizic acid or RA190 in combination with glycyrrhizic acid in the preparation of drugs for inhibiting MDV replication, in the preparation of drugs for preventing or treating Marek's disease, and in the preparation of drugs for inhibiting tumor formation in chickens with Marek's disease. Through experiments on inhibiting the activity of virus-encoded enzymes, drug toxicity experiments at the CEF cell level, virus CPE inhibition experiments, and chicken MD model experiments, it is proved that the RA190 and glycyrrhizic acid alone or in combination can effectively inhibit the replication of Marek's disease virus and the generation of chicken MD tumors, and have good application prospects in poultry breeding.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the application field of natural compounds, and in particular to the application of a natural compound glycyrrhizic acid and an artificially synthesized compound RA190 alone or in combination as drugs for inhibiting the replication of Marek's disease virus and resisting the occurrence of Marek's disease. Background Art

[0002] Chickens infected with the pathogenic serotype I Marek's disease virus (MDV) will cause Marek's disease (MD), which is a highly lethal viral infectious disease with multiple visceral tumors. Chickens are the most important natural host of MDV. MDV belongs to the cell-bound herpesvirus family, and its molecular structure and genetic composition are similar to those of alpha herpesviruses.

[0003] At present, the main means of defending against MD is to vaccinate against MD. Studies have shown that vaccination against MD can protect chickens from developing MD malignant tumors, but chickens immunized with MD vaccines can still be infected with MDV, and MD vaccines cannot prevent the replication, maturation, and release of MDV in chickens. Therefore, chickens immunized with MD vaccines become new sources of infection for MDV, and the immune pressure of the vaccine further promotes the continuous enhancement of MDV virulence, resulting in the emergence of more virulent MDV strains. Therefore, MDV is still an important threat to the poultry industry. However, preventing MDV from replicating in chicken cells is an effective way to curb the proliferation, spread, and virulence enhancement of MDV, and is also the key to controlling MD outbreaks and enhancing the defensive effect of vaccines.

[0004] The CAS number of RA190 is 1617495-03-0 and its molecular formula is C 28 H 23 Cl 5 N 2 O 2 , with a relative molecular mass of 596.76. Studies have found that RA190 covalently binds to cysteine ​​88 of the ubiquitin receptor RPN13 in the 19S regulatory particle and inhibits proteasome function, triggering the rapid accumulation of polyubiquitin proteins. Multiple myeloma (MM) lines, even myeloma resistant to bortezomib, are sensitive to RA190 through endoplasmic reticulum stress-related apoptosis. RA190 stabilizes the target of human papillomavirus E6 oncoprotein and preferentially kills HPV-transformed cells. RA190 also plays a role in the treatment of cartilage development and primary liver cancer, but there have been no reports of RA190 against Marek's disease or any inhibition of MDV viral replication and activity.

[0005] Other Chinese names for glycyrrhizic acid include glycyrrhizin, glycyrrhizic acid, qianglin, glycyrrhizic acid glycoside, glycyrrhizin, glycyrrhizin, glycyrrhizin, glycyrrhizin protein, sweetener licorice, α-glycyrrhizic acid, etc. Its English name is Glycyrrhizic acid, with a CAS number of 1405-86-3 and a molecular formula of C 42 H 62 O 16 , molecular weight is 822.94. Glycyrrhizic acid is the main component of licorice, with a special sweet taste, and is widely used in food, medicine, cosmetics and tobacco industries. Glycyrrhizic acid has been used clinically to treat chronic hepatitis. Glycyrrhizic acid can significantly inhibit HIV replication in blood mononuclear cells of HIV-positive patients in vitro. Glycyrrhizic acid can also reduce the morbidity and mortality of mice infected with lethal doses of influenza virus. Glycyrrhizic acid has a strong inhibitory effect on the replication of SARS-CoV coronavirus FFM-1 and FFM-2 strains. Glycyrrhizic acid also has clinical effects such as anti-inflammatory, anti-allergic, detoxification and liver protection. Glycyrrhizic acid plays a role in various cells and various life processes, but there has been no report on glycyrrhizic acid's anti-Marek's disease or any inhibition of MDV virus replication and activity. Summary of the invention

[0006] In order to overcome the deficiencies of the prior art, the present invention provides a drug for inhibiting Marek's disease virus, wherein the drug comprises RA190 and / or glycyrrhizic acid.

[0007] The present invention provides a drug that can resist the occurrence of chicken MD, inhibit the replication of MDV in chicken cells, improve the defense effect of MD vaccine, and curb the enhancement of MDV toxicity. The present invention provides a new use of RA190 and glycyrrhizic acid alone or in combination as drugs for inhibiting MDV replication and resisting chicken Marek's disease. Based on the MDV049 protease and UL23 thymidine kinase activity inhibition system encoded by MDV, as well as cell inoculation virus and Marek's disease animal models, RA190 and glycyrrhizic acid alone or in combination can effectively inhibit the replication of MDV and the generation of tumors in the experimental animal model of virus attack under safe dosage.

[0008] Preferably, the drug is used to inhibit the replication of Marek's disease virus (MDV), including RA190 and glycyrrhizic acid alone or in combination. RA190 and glycyrrhizic acid described in the present invention, alone or in combination, have the effect of resisting MDV and MD.

[0009] Unless otherwise specified, the drugs used in the present invention are all commercial reagents or mixtures of reagents artificially synthesized using existing technical methods. RA190 and glycyrrhizic acid preparation or extraction methods are existing technical contents and are not the subject of protection of the present invention.

[0010] Preferably, in any of the above items, the drug is RA190.

[0011] Preferably, any one of the above items is that the drug is glycyrrhizic acid.

[0012] Preferably, any of the above items is that the drug is RA190 and glycyrrhizic acid, and the combined use of RA190 and glycyrrhizic acid greatly improves the effect of the drug in inhibiting Marek's disease virus.

[0013] RA190 inhibits the activity of MDV049 protease encoded by MDV, and glycyrrhizic acid inhibits the activity of UL23 thymidine kinase encoded by MDV. The functions of MDV049 protein and UL23 have not been explained in detail. The present invention performs high-throughput screening on more than 5,000 compounds, and fortunately finds that the RA190 has the effect of inhibiting the activity of MDV049 protease, and glycyrrhizic acid has the effect of inhibiting the activity of UL23 thymidine kinase. According to the research of the present invention, the RA190 inhibits the replication of MDV at the cellular level by inhibiting the MDV049 protease or the glycyrrhizic acid inhibits the UL23 thymidine kinase, and has no significant inhibitory effect on the signaling pathways and proteins of the chicken cells themselves.

[0014] RA190 as a protease inhibitor and glycyrrhizic acid as a thymidine kinase inhibitor can affect the functions of multiple signal pathways and proteins in cells. The research of the present invention shows that RA190 specifically inhibits the protease activity of MDV049 and glycyrrhizic acid specifically inhibits the thymidine kinase activity of UL23 of MDV.

[0015] The RA190 and / or glycyrrhizic acid inhibit the replication of MDV in cells. By adding the RA190 and glycyrrhizic acid alone or in combination to the culture system of chicken cells infected with MDV, the replication of MDV is significantly inhibited. Preferably, the RA190 and glycyrrhizic acid inhibit the replication of the virus at the level of CEF cells (chicken embryo fibroblasts) or DF-1 cells (chicken embryo fibroblast cell line) infected with MDV.

[0016] Preferably, any of the above items is that when used alone, the RA190 has an effective concentration of 0.01 to 100 μM at the cellular level. Preferably, RA190 at a concentration of 0.01 μM, 0.12 μM, 0.02 μM, 0.04 μM, 0.1 μM, 1 μM, 10 μM, 20 μM, 30 μM, 40 μM, 50 μM, 60 μM, 70 μM, 80 μM, 90 μM, 100 μM and the range therebetween effectively inhibits the replication of MDV in cells infected with MDV, while having no toxic side effects on the cells themselves. Preferably, the concentration of RA190 is greater than 0.01 μM, and the concentration of RA190 greater than 0.01 μM can significantly reduce the replication of the virus. More preferably, the concentration of RA190 is greater than 1.2 μM. Preferably, when the concentration reaches 1.2 μM, the virus replication in cells and infection of cells can be substantially completely inhibited, and within this concentration range, the drug does not cause significant damage to cells.

[0017] Preferably, any of the above items is that when used alone, the glycyrrhizic acid has an effective concentration of 5 to 300 μM at the cell level. Preferably, glycyrrhizic acid at concentrations of 5 μM, 10 μM, 20 μM, 50 μM, 80 μM, 150 μM, 200 μM, 250 μM, and 300 μM effectively inhibits the replication of MDV in cells infected with MDV, and has no toxic side effects on the cells themselves. Preferably, 5 μM glycyrrhizic acid inhibits the replication of MDV at the CEF cell level; preferably, the concentration of glycyrrhizic acid is greater than 5 μM, and when the concentration of glycyrrhizic acid is greater than 5 μM, the replication of the virus can be significantly reduced. More preferably, the concentration of glycyrrhizic acid is greater than 20 μM; preferably, when the concentration reaches 20 μM, the replication of the virus in the cell and the infection of the cell can be basically completely inhibited, and the drug does not cause significant damage to the cell in this concentration range.

[0018] Any of the above items is preferably that the RA190 has an effective concentration of 0.01 to 100 μM at the cellular level, the glycyrrhizic acid has an effective concentration of 5 to 300 μM at the cellular level, and RA190 and glycyrrhizic acid are used in combination within this concentration range. Further preferably, when the drug is RA190 and glycyrrhizic acid used in combination at the cellular level, within the concentration range of 0.01 to 100 μM RA190 and 5 to 300 μM glycyrrhizic acid, the RA190: glycyrrhizic acid molar concentration ratio can play a synergistic inhibitory effect on MDV replication under the conditions of 1:5-1:80, and the inhibitory effect is best under the combined use condition of 1:20. Preferably, the RA190: glycyrrhizic acid molar concentration ratio is 1:5, 1:10, 1:20, 1:40, 1:80.

[0019] Preferably, any of the above items is that the cells at the cell level are CEF cells or DF-1 cells. Preferably, 0.01 μM RA190 inhibits MDV replication in CEF cells.

[0020] Any of the above items is preferably used as a drug for preventing or resisting Marek's disease. RA190 and glycyrrhizic acid are used alone or in combination.

[0021] Preferably, any of the above items is that the dosage of the drug used in animals is RA190 with an action dosage of 0.01 to 510 μg / (kg·d). Preferably, the dosage of RA190 used in animals is not less than 0.01 μg / (kg·d). When the dosage of RA190 is greater than 0.01 μg / (kg·d), it significantly inhibits the occurrence of symptoms such as internal bleeding and tumors in chickens infected with MDV, and inhibits the replication of MDV in chicken T cells, that is, RA190 and glycyrrhizic acid can inhibit the occurrence of Marek's disease in chickens.

[0022] Preferably, any of the above items is that the dosage of the drug used in animals is 3 to 210 mg / (kg·d) of glycyrrhizic acid. Preferably, the dosage of glycyrrhizic acid used in animals is not less than 3 mg / (kg·d). When the dosage of glycyrrhizic acid is greater than 3 mg / (kg·d), it significantly inhibits the occurrence of symptoms such as internal bleeding and tumors in chickens infected with MDV, and inhibits the replication of MDV in chicken T cells, that is, RA190 and glycyrrhizic acid can inhibit the occurrence of Marek's disease in chickens.

[0023] Any of the above items is preferably that the dosage of the drug used in animals is RA190 at an effective dosage of 0.01 to 510 μg / (kg·d), glycyrrhizic acid at an effective dosage of 3 to 210 mg / (kg·d), and RA190 and glycyrrhizic acid are used in combination within this dosage range. When the dosage of RA190 is greater than 0.01 μg / (kg·d) and the dosage of glycyrrhizic acid is greater than 3 mg / (kg·d), either alone or in combination, the appearance of symptoms such as internal bleeding and tumors in chickens infected with MDV can be significantly inhibited, and the replication of MDV in chicken T cells can be inhibited, that is, RA190 and glycyrrhizic acid can inhibit the occurrence of Marek's disease in chickens.

[0024] Any of the above items is preferably that the dosage used in the animal is the dosage used in chickens. The RA190 is used as an MDV049 protease inhibitor, and glycyrrhizic acid is used as an UL23 thymidine kinase inhibitor. The present invention first discovered that the RA190 inhibits the activity of the MDV049 protease in the Marek's disease animal model, but has no inhibitory effect on the protease in the chicken itself; it is also found that glycyrrhizic acid inhibits the activity of the UL23 thymidine kinase in the Marek's disease animal model, but has no inhibitory effect on the thymidine kinase in the chicken itself, that is, RA190 and glycyrrhizic acid have no toxic side effects on chickens. The dosage can inhibit the activity of the MDV049 protease and UL23 thymidine kinase, can significantly inhibit the occurrence of symptoms such as internal bleeding and tumors in chickens infected with MDV, and inhibits the replication of MDV in chicken T cells, that is, inhibits the occurrence of Marek's disease in chickens.

[0025] Preferably, any of the above items is that the administration of the drug includes at least one of oral administration, intraperitoneal injection or intramuscular injection.

[0026] Preferably, any of the above items has a single dosage of: when administered orally, the dosage of RA190 is 10 to 510 μg / (kg·d).

[0027] Preferably, any of the above items has a single dosage of: when taken orally, the dosage of glycyrrhizic acid is 18 to 210 mg / (kg·d).

[0028] Preferably, any of the above items is that, when orally administered, the combined dosage of RA190 and glycyrrhizic acid is: RA190 dosage is 10-510 μg / (kg·d), and glycyrrhizic acid dosage is 18-210 mg / (kg·d).

[0029] Preferably, any of the above items is used as a single dosage: when injected intraperitoneally, the dosage of RA190 is 0.01 to 120 μg / (kg·d).

[0030] Preferably, any of the above items is used alone in a dosage of 3 to 120 mg / (kg·d) for intraperitoneal injection.

[0031] Preferably, in any of the above items, when injected intraperitoneally, the combined dosage of RA190 and glycyrrhizic acid is: RA190 dosage is 0.01-120 μg / (kg·d), and glycyrrhizic acid dosage is 3-120 mg / (kg·d).

[0032] Preferably, any of the above items is used as a single dosage: when injected intramuscularly, the dosage of RA190 is 2 to 240 μg / (kg·d).

[0033] Preferably, any of the above items is used alone in a dosage of 11 to 180 mg / (kg·d) for intramuscular injection.

[0034] Preferably, in any of the above items, when injected intramuscularly, the combined dosage of RA190 and glycyrrhizic acid is: RA190 dosage is 2-240 μg / (kg·d); glycyrrhizic acid dosage is 11-180 mg / (kg·d).

[0035] Preferably, any of the above items is that RA190 and glycyrrhizic acid are used in combination within the dosage range of oral administration, intraperitoneal injection, and intramuscular injection of the above-mentioned single medications, respectively; further preferably, within the above-mentioned dosage range, the RA190: glycyrrhizic acid dosage ratio can exert a synergistic inhibition of MDV replication and anti-MD effects in animals under the conditions of 1:200-1:2000, and the inhibition effect is best under the combined medication condition of 1:1000. The preferred combined medication RA190: glycyrrhizic acid dosage ratio is 1:200, 1:500, or 1:2000.

[0036] Any of the above is preferably that the RA190, when taken orally, is in a dosage of 10 to 510 μg / (kg·d), preferably, the best oral dosage of RA190 is 200 μg / (kg·d), and other preferred oral dosages of RA190 are 10, 15, 20, 25, 40, 60, 80, 100, 150, 170, 200, 220, 250, 300, 350, 400, 450, 510 μg / (kg·d), and ranges therebetween; when injected intraperitoneally, the dosage of RA190 is 0.01 to 120 μg / (kg·d), preferably, the best intraperitoneal dosage of RA190 is 25μg / (kg·d), other preferred RA190 intraperitoneal injection doses are 0.01, 0.1, 0.5, 1.0, 2.0, 5.0, 10, 25, 50, 100, 120μg / (kg·d) and ranges therebetween; when injected intramuscularly, the RA190 dose is 2 to 240μg / (kg·d), preferably, the best intramuscular injection dose of RA190 is 40μg / (kg·d), and other preferred RA190 intramuscular injection doses are 2, 7, 12, 19, 26, 38, 42, 72, 97, 113, 144, 184, 209, 220, 240μg / (kg·d) and ranges therebetween.

[0037] Any of the above is preferably that the glycyrrhizic acid, when taken orally, is in a dosage of 18 to 210 mg / (kg·d), preferably, the best oral dosage of glycyrrhizic acid is 75 mg / (kg·d), and other preferred oral dosages of glycyrrhizic acid are 18, 30, 40, 60, 80, 100, 150, 170, 210 mg / (kg·d) and ranges therebetween; when injected intraperitoneally, the dosage of glycyrrhizic acid is 3 to 120 mg / (kg·d), preferably, the best intraperitoneal dosage of glycyrrhizic acid is 30 mg / (kg·d). d), other preferred glycyrrhizic acid intraperitoneal injection doses are 3, 5, 10, 20, 40, 60, 80, 100, 120 mg / (kg·d) and ranges therebetween; when injected intramuscularly, the dose of glycyrrhizic acid is 11 to 180 mg / (kg·d), preferably, the best intramuscular injection dose of glycyrrhizic acid is 60 mg / (kg·d), and other preferred intramuscular injection doses of glycyrrhizic acid are 11, 22, 36, 50, 60, 80, 100, 120, 140, 160, 180 mg / (kg·d) and ranges therebetween.

[0038] Preferably, any of the above items is a combination of RA190 and glycyrrhizic acid within the dosage range, which includes at least one dosage range of oral administration, intraperitoneal injection or intramuscular injection.

[0039] Preferably, any of the above items is that the MDV is serotype I MDV.

[0040] Preferably, any of the above items is that the RA190 and glycyrrhizic acid, used alone or in combination within the dosage range of the present invention, inhibit the formation of MD tumors in chickens infected with MDV.

[0041] The present invention also provides the use of RA190 or glycyrrhizic acid or the combination of RA190 and glycyrrhizic acid in the preparation of drugs for inhibiting MDV replication.

[0042] The present invention also provides the use of RA190 or glycyrrhizic acid or RA190 in combination with glycyrrhizic acid in the preparation of a drug for preventing or treating Marek's disease.

[0043] The present invention also provides the use of RA190 or glycyrrhizic acid or the combination of RA190 and glycyrrhizic acid in the preparation of a medicine for inhibiting tumor formation in chickens suffering from Marek's disease.

[0044] The present invention also provides the use of RA190 as an inhibitor of MDV049 protease. Preferably, the MDV049 protease is the MDV049 protease encoded by MDV.

[0045] The present invention also provides the use of RA190 in preparing an MDV049 protease inhibitor. Preferably, the MDV049 protease is the MDV049 protease encoded by MDV.

[0046] The present invention also provides the use of glycyrrhizic acid as a UL23 thymidine kinase inhibitor. Preferably, the UL23 thymidine kinase is the UL23 thymidine kinase encoded by MDV.

[0047] The present invention also provides the use of glycyrrhizic acid in the preparation of a UL23 thymidine kinase inhibitor. Preferably, the UL23 thymidine kinase is the UL23 thymidine kinase encoded by MDV.

[0048] The beneficial effect of the present invention is that the present invention screens out for the first time the single and combined use of RA190 and glycyrrhizic acid, which can not only inhibit the activity of MDV049 protease and UL23 thymidine kinase at the enzyme level, inhibit the replication of MDV at the cell level, but also inhibit MD tumor growth and visceral bleeding at the animal level, and has a very strong effect. Preferably, the dosage of RA190 used as an MDV049 protease inhibitor, the dosage of glycyrrhizic acid used as a UL23 thymidine kinase inhibitor, and the dosage used in the combined use in the present invention are much lower than the effective dosage of RA190 and glycyrrhizic acid in conventional use, have the advantage of small dosage, can be widely used as an anti-MD drug in the production practice of poultry industry to defend against MD, and have good economic value and research significance.

[0049] In the present invention, RA190 as an inhibitor of MDV049 protease and glycyrrhizic acid as an inhibitor of UL23 thymidine kinase are mainly antiviral in the treatment of Marek's disease, that is, the treatment time for Marek's disease is the stage when the virus is infected but no tumor occurs. The enzyme activities of MDV049 protease and UL23 thymidine kinase inhibit viral replication and the production of tumor cells, thereby playing a therapeutic role.

[0050] At present, the virulence of MDV is constantly increasing, and chickens vaccinated with the vaccine may still suffer from Marek's disease. Under this situation, the present invention has found a new way to control Marek's disease, and can enhance the effect of MD vaccine, and has a wide application prospect. BRIEF DESCRIPTION OF THE DRAWINGS

[0051] Figure 1 RA190 according to the preferred embodiment 1 of the present invention inhibits the protease activity of MDV049 encoded by MDV.

[0052] Figure 2 This is the result of glycyrrhizic acid inhibiting UL23 thymidine kinase activity in preferred embodiment 2 of the present invention.

[0053] Figure 3These are the results of the cytotoxicity of RA190 and glycyrrhizic acid alone or in combination on CEF cells according to the preferred embodiment 3 of the present invention.

[0054] Figure 4 This is a diagram of cytopathic effect (CPE) after three days of treatment with MDV or MDV+drug according to Example 3 of the present invention.

[0055] Figure 5 This is a graph showing the relationship between the CPE areas of RA190, glycyrrhizic acid alone and in combination with MDV in Experimental Example 3 of the present invention.

[0056] Figure 6 This is a graph showing the relationship between the MDV genome copy number in CEF cells of Example 3 of the present invention and the single-drug and combined-drug use of RA190 and glycyrrhizic acid.

[0057] Figure 7 This is a graph showing the relationship between the MDV genome copy number in the MD model chicken T cells of Example 4 of the present invention and the use of RA190 and glycyrrhizic acid alone and in combination.

[0058] Figure 8 This is a relationship diagram between the incidence of MD in MD model chickens in Example 4 of the present invention and the use of RA190 and glycyrrhizic acid alone and in combination.

[0059] Fig. 9 This is a schematic diagram of the relationship between the single medication and combined medication of RA190 and glycyrrhizic acid in Example 4 of the present invention and the number of tumors in MD model chickens. DETAILED DESCRIPTION

[0060] The present invention is further described in detail below through the accompanying drawings and specific embodiments.

[0061] Example 1

[0062] RA190 inhibits the protease activity of MDV049 encoded by MDV.

[0063] Enzyme reaction system: 2.5nM MDV049 protease (Genbank#AAG14229.1, preparation and activity analysis methods refer to: Wang Mengyun (mentor: Ai Yongxing). Activity and enzymatic specificity analysis of MDV-encoded deubiquitinase UL36 (Thesis) (2017).), 1× reaction buffer (50mM HEPES pH7.8, 0.1mg / mL BSA, 0.5mM EDTA, 1mM DTT), 70nM fluorescent substrate Ub-Rho110 was added to the reaction, incubated at 37°C, and the fluorescence intensity change was measured on a fluorescence spectrophotometer to obtain the initial reaction rate. The reaction systems with different concentrations of RA190 were used as inhibitor groups "10μM RA190 group", "50μM RA190 group", and "100μM RA190 group", and the reaction system without drug addition was the inhibitor-free group as the "control group". The results are as follows Figure 1 In the "control group", MDV049 protease hydrolyzed Ub-Rho110 normally with a good initial reaction rate, while the activity of MDV049 in each inhibitor group was inhibited and the initial reaction rate decreased. This result shows that RA19 inhibits the enzymatic activity of MDV049 encoded by MDV.

[0064] Example 2

[0065] Glycyrrhizic acid inhibits UL23 thymidine kinase activity

[0066] Enzymatic reaction system: containing 1×HEPES reaction buffer (50mM HEPES, 150mM NaCl, 5mM MgCl2, pH7.5), 500mM ATP, 200mM dTR, 2μM UL23 thymidine kinase (Genbank#AAG14216.1, preparation and activity analysis method reference: Wang Rui (mentor: Sun Aijun). Comparative structural analysis and in vitro activity verification of thymidine kinase encoded by MDV and other alpha herpes viruses (Thesis) (2023). (DOI: 10.27117 / d.cnki.ghenu.2023.000615)), add water to 1mL, react at 37℃ for 1h, boil in water bath for 10min to end the reaction, filter with 0.22μm filter, detect dTMP generation by HPLC, detect wavelength at 260nm, and detect the content of collected dTMP product. The group without glycyrrhizic acid was the "control group", and the reaction systems with different concentrations of glycyrrhizic acid under the same conditions were the "20 μM glycyrrhizic acid group", "60 μM glycyrrhizic acid group", and "110 μM glycyrrhizic acid group". Figure 2 Compared with the control group, the dTMP production in each glycyrrhizic acid-treated group was significantly reduced. This result indicates that glycyrrhizic acid inhibits the thymidine kinase activity of UL23 encoded by MDV.

[0067] Example 3

[0068] Preparation of CEF cells and infection with MDV:

[0069] 1. Take a 10-day-old SPF chicken embryo and wipe it with alcohol cotton, starting from the air chamber and wiping around to disinfect. Then put the chicken embryo into the clean bench with the air chamber facing upwards. Carefully use autoclaved tweezers to break the air chamber and remove the eggshell.

[0070] 2. Use new sterile tweezers to peel off the chorioallantoic membrane, discard the egg shell and vitelline membrane. Use sterile tweezers to clamp the head of the chicken embryo and gently move it to the plate.

[0071] 3. Fix the head with sterile tweezers, cut off the head, limbs, and organs with sterile scissors, and rinse repeatedly with sterile PBS until colorless.

[0072] 4. Use sterile scissors to cut the tissue blocks into small pieces until there are no large particles of tissue, add 8 mL of sterile PBS to wash, let it stand for 1 minute, and use a pipette to discard the suspension mixed with red blood cells and tissue fragments.

[0073] 5. Add 0.25% trypsin at 3 to 5 times the volume of the tissue block, place it in a 37°C water bath for digestion for 15 minutes, and shake it continuously during the digestion. When the tissue turns white and loose, add FBS with a final concentration of 10% to terminate the digestion, and repeatedly blow the cells to disperse them into single cells.

[0074] 6. After filtering the cell suspension with sterile gauze, add the filtrate into a centrifuge tube, centrifuge at 1000r / min at room temperature for 8 minutes, and discard the supernatant.

[0075] 7. Resuspend the cells in DMEM medium containing 10% FBS, dilute to the appropriate concentration, add to the cell culture flask, and place at 37°C, 5% CO 2 The cells were cultured in an incubator until they grew into a monolayer and reached 80% confluence.

[0076] 8. Remove the virus from liquid nitrogen and dilute it with culture medium.

[0077] 9. Add the virus to the monolayer of CEF cells.

[0078] CCK-8 assay to detect the cytotoxicity of RA190 or glycyrrhizic acid on CEF:

[0079] 1. RA190 treatment of CEF cells: 20,000 CEF cells were plated in each well of a 96-well plate, RA190 was diluted into a concentration gradient with culture medium, and the culture medium containing the RA190 concentration gradient was added to the 96-well plate, with a volume of 100 μL per well, and the plate was incubated at 37°C and 5% CO 2 Culture in the incubator for 72 hours.

[0080] 2. CCK-8 method was used to detect cell viability. The specific operation was as follows: 10 μL CCK-8 solution was added to each well of the above 96-well plate, and then the culture plate was placed in 37°C, 5% CO 2 Incubate in the incubator for 3 hours, measure the absorbance (OD value) at a wavelength of 450nm with an enzyme marker, and take the average of the OD values ​​of each parallel well. Cell viability % = (OD450 of drug-treated cells-OD450 of blank cells) / (OD450 of control cells-OD450 of blank cells) × 100%, and the experiment was repeated three times.

[0081] 3. Using the same method as steps 1 and 2, detect the cytotoxicity of glycyrrhizic acid on CEF.

[0082] The safe concentration of RA190 or glycyrrhizic acid for CEF cells was determined when the cell viability was not lower than 95% of the group without drug treatment. Figure 3 , the cell viability of 120μM RA190 and 320μM glycyrrhizic acid treated alone was above 95%, but when used in combination at this concentration, the cell viability was less than 95%, while the cell viability of 100μM RA190 and 300μM glycyrrhizic acid was above 95% whether used alone or in combination. Therefore, the safe concentration of RA190 for CEF cells is <100μM, and the safe concentration of glycyrrhizic acid for CEF cells is <300μM.

[0083] RA190 and glycyrrhizic acid inhibit MDV replication alone or in combination at the CEF cell level:

[0084] 1. Morphological observation, specifically: 200,000 cells were plated in each well of a 6-well plate. After the cells adhered to the wall and grew into a monolayer, the culture medium was replaced with a culture medium containing an equal volume of DMSO, 0.6 μM RA190, or 12 μM glycyrrhizic acid, respectively, or both, and 200 PFU of virus was inoculated into each well. After three days, the CPE caused by MDV was observed under a microscope. Figure 4 As shown, the CPE area was recorded and graphed using Graph Pad Prism 10, with the horizontal axis representing the treatment method and the vertical axis representing the CPE area, as shown in Figure 5As shown, the experiment was repeated three times. The results showed that compared with the control group, the CPE area on CEF cells was significantly reduced by RA190 and glycyrrhizic acid alone or in combination (RA190 group decreased by 65.85%, glycyrrhizic acid group decreased by 72.82%, and combined treatment decreased by 95.30%). The software CompuSyn (v1.0.1) was used to analyze the combination index (CI). It was found that under the condition of a molar concentration ratio of RA190: glycyrrhizic acid = 1:20, the combined treatment had the best effect, which was better than the single treatment, and was a synergistic effect (CI <0.3) (Table 3). It shows that RA190 and glycyrrhizic acid alone or in combination can inhibit the formation of MDV-induced CEF cell lesions, and the combined treatment effect is better than the single treatment.

[0085] 2. Copy number changes

[0086] a. Establishment of standard curve equation

[0087] According to the MDV049 gene sequence in the MDV genome (GenBank#AF243438.1), a fluorescence quantitative PCR standard plasmid pM18T-MDV049 (500) (comprising the nucleic acid sequence of the N-terminal 500 amino acids of the MDV049 gene sequence) was constructed, and a pair of real-time fluorescence quantitative PCR primers were designed based on the standard plasmid sequence, the upstream primer is shown in Seq ID NO: 1, and the downstream primer is shown in Seq ID NO: 2. By performing Q-PCR on the standard plasmid, a standard curve with a good linear relationship was drawn using the CT value and the standard plasmid copy number, and the experiment was repeated three times.

[0088] b. Determination of viral copy number

[0089] 200,000 cells were plated in each well of a 6-well plate. After the cells adhered to the wall and grew into a monolayer, the culture medium was replaced with a culture medium containing an equal volume of DMSO, 0.6 μM RA190, or 12 μM glycyrrhizic acid, either alone or together, and 200 PFU of drugs were inoculated in each well. The genome was extracted from each well. Q-PCR was performed using the above primers. Quantitative analysis was performed based on the results. The CT values ​​obtained for each group were substituted into the standard curve to obtain the copy number. Graph Pad Prism 10 was used to draw a graph. The horizontal axis is the drug concentration, and the vertical axis is the copy number, as shown in Figure 1. Figure 6As shown. The experiment was repeated three times. The results showed that compared with the control group, the number of MDV copies in CEF cells was significantly reduced by RA190 and glycyrrhizic acid alone or in combination (RA190 group decreased by 60.36%, glycyrrhizic acid group decreased by 65.00%, and combined treatment decreased by 92.75%). This shows that RA190 and glycyrrhizic acid alone or in combination can inhibit the replication of MDV in CEF cells, and the effect of combined treatment is better than that of single treatment.

[0090] c. Evaluation of combined medication

[0091] The above CPE area and MDV copy number changes corresponded to the corresponding single and combined drug concentrations. The software CompuSyn (v1.0.1) was used to analyze the Combination Index (CI). It was found that when the molar concentration ratio was RA190 (0.6 μM): glycyrrhizic acid (12 μM) = 1:20, the combined drug effect was the best, which was better than single drug use and belonged to the synergistic inhibitory effect (CI = 0.232).

[0092] Example 4

[0093] RA190 and glycyrrhizic acid alone or in combination inhibit MDV replication and MD occurrence in chicken MD disease model

[0094] The specific operation is as follows: 1-day-old SPF chickens were taken, and the MDV titer was 200 PFU. The challenge method was intraperitoneal inoculation. These challenged chickens were given intraperitoneal injections of RA190, glycyrrhizic acid alone and in combination every day. The experimental group was given an effective dose of the drug (Table 1), and the group that was not treated with the drug and only injected with an equal amount of saline was used as the control group. There were 5 chickens in each group. Blood was collected from the blood vessels under the wings 20 days after the challenge, and T lymphocytes were isolated. The MDV gene copy number was quantitatively analyzed based on the number of 200,000 cells, such as Figure 7 The incidence of MD in each group of chickens within 50 days after infection was calculated. Figure 8 . 50 days after infection or when the animals were close to death during this period, autopsies were performed and the number of visceral tumors was recorded, with the number of tumors in the liver and spleen being counted and plotted. Fig. 9. Compared with the control group, the incidence of MD in MDV-challenged chickens in each drug administration group decreased significantly, and the incidence in the combined drug group decreased more significantly (the RA190 group decreased by 45.45%, the glycyrrhizic acid group decreased by 51.52%, and the combined drug group decreased by 94.95%); the number of MDV genome copies in T cells decreased significantly (the RA190 group decreased by 71.25%, the glycyrrhizic acid group decreased by 78.75%, and the combined drug group decreased by 91.25%); the number of visceral tumors decreased significantly, and no significant tumors appeared in some individuals in the combined drug group (the RA190 group decreased by 62.92%, the glycyrrhizic acid group decreased by 67.42%, and the combined drug group decreased by 91.01%). This shows that RA190 and glycyrrhizic acid alone and in combination can inhibit the replication of MDV in chickens and inhibit the occurrence of MD in chickens.

[0095] Example 5

[0096] RA190 and glycyrrhizic acid were used orally, intraperitoneally, and intramuscularly in combination to act on the chicken MD disease model. Within the effective range of medication in Table 1, the experiment showed that the three administration methods can effectively inhibit the replication of MDV in chickens and inhibit the occurrence of chicken MD. Within the same dosage range as the single medication, RA190 and glycyrrhizic acid were combined in different proportions to analyze the anti-MDV and MD effects. The software CompuSyn (v1.0.1) was used to analyze the combination index (CI). It was found that under the condition of the dosage ratio of RA190: glycyrrhizic acid = 1:1000, the combination effect was the best, and the effect was better than the single medication, which was a synergistic effect (CI<0.6). Table 1 shows the safety range, effective range and optimal dose of RA190, glycyrrhizic acid alone and in combination in the three administration methods and cell level experiments. Table 2 shows the effects of the three administration methods and combined medication.

[0097] Table 1:

[0098]

[0099]

[0100] Table 2:

[0101]

[0102] Example 6

[0103] Example 6 The CI analysis was used to compare the effects of single drug use or the synergistic effects of combined drug use. The CI value calculation and analysis showed (Table 3) that within the effective range of RA190 and glycyrrhizic acid, the best CPE inhibition effect was achieved when the molar concentration ratio of RA190: glycyrrhizic acid at the cell level was 1:20, and the best anti-MD and MDV replication inhibition effect was achieved when the dosage ratio of RA190: glycyrrhizic acid at the animal level was 1:1000.

[0104] Table 3:

[0105]

[0106]

[0107] Example 7

[0108] Verify the specific inhibitory effect of RA190 on MDV049 protease and the specific inhibitory effect of glycyrrhizic acid on UL23 thymidine kinase. The experiment showed that RA190 and glycyrrhizic acid had no inhibitory effect on chicken USP1, USP7, USP8, USP2, USP5, USP10, USP13, USP15, USP16, USP20, USP33, USP18, USP19, USP28, USP37, USP46, USP47, USP51, CYLD, UCH-L1, UCH-L5, OTU1, OTU4, OTU7 and other proteases, and had no inhibitory effect on chicken thymidine kinase (>114μM).

[0109] The experimental method is the same as the MDV049 protease and UL23 thymidine kinase inhibition experiment. Chicken TK, USP1, USP7, USP8 and other enzymes use 1-3nM enzyme concentration, and the inhibitor concentration >114μM has no significant inhibitory effect on the above enzyme activities.

[0110] References: Experimental methods and identification standards: Chen, J., et al., Selective and cell-active inhibitors of the USP1 / UAF1 deubiquitinase complex reverse cisplatin resistance in non-small cell lung cancer cells. Chem Biol, 2011. 18(11): p. 1390-400.

[0111] Example 8

[0112] The present invention screens MDV049 protease and UL23 thymidine kinase inhibitors.

[0113] The present invention uses more than 5,000 protease inhibitors and thymidine kinase inhibitors from Topscience and MedChemExpress for high-throughput screening. Among them, human USP1 inhibitors ML-323 (Cas No. 1572414-83-5), PR-619 (Cas No. 2645-32-1), SJB3-019A (Catalog No. B1307), Pimozide (Cas No. 2062-78-4), GW7647 (Cas No. 265129-71-3), Flupenthixol (Cas No. 51529-01-2), Trifluoperazine (Cas No. 440-17-5), Rottlerin (Cas No. 82-08-6), and USP7 / 8 inhibitors HBX19818 (Cas No. 1426944-49-1), P22077 (Cas No. 1247819-59-5), GNE-6640 (Cas No.2009273-67-8), GNE-6776 (Cas No.2009273-71-4), NSC 632839 (Cas No.157654-67-6), BAY 11-7082 (CasNo.19542-67-7), USP7-IN-1 (Cas No.1381291-36-6), C598-0466 (Catalog No.A8740), NSC632839 (Cas No.157654-67-6) had no inhibitory effect on MDV049 protease (>114μM), and YMU1, MtTMPK-IN-8, MtTMPK-IN-9, MtTMPK-IN-7, MtTMPK-IN-2, 2'-Deoxy-L-guanosine, Sorivudine, etc. had no inhibitory effect on UL23 thymidine kinase encoded by MDV (>114μM).

[0114] Example 9

[0115] The optimal doses of RA190 and glycyrrhizic acid under various administration methods in Table 1 were administered to healthy chickens to prevent Marek's disease. The results showed that RA190 and glycyrrhizic acid alone and in combination as preventive drugs for Marek's disease effectively reduced the infection rate of MDV in chickens and the incidence of MD. It also proved that oral, intramuscular and intraperitoneal injections are all effective administration methods for prevention.

[0116] The present invention verifies the above results by preventing MDV infection in chickens after administration, and then detecting the MDV infection rate and MD incidence rate of the chickens, as well as the virus level in the body.

[0117] The above embodiments are merely examples for the purpose of clear explanation, and are not intended to limit the implementation methods. For those skilled in the art, other different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to list all the implementation methods here. The obvious changes or modifications derived therefrom are still within the scope of protection of the invention.

Claims

1. Use of RA190 or RA190 in combination with glycyrrhizic acid in the preparation of a drug for inhibiting the replication of Marek's disease virus, characterized in that: When RA190 is used alone, its effective concentration at the cellular level is 0.01-100 μM; when RA190 and glycyrrhizic acid are used in combination, the molar concentration ratio of RA190: glycyrrhizic acid is 1:5-1:

80.

2. Use of RA190 or RA190 in combination with glycyrrhizic acid in the preparation of a drug for preventing or treating Marek's disease, characterized in that: When RA190 is used alone, its effective concentration at the cellular level is 0.01-100 μM; when RA190 and glycyrrhizic acid are used in combination, the molar concentration ratio of RA190: glycyrrhizic acid is 1:5-1:

80.

3. Use of RA190 or RA190 in combination with glycyrrhizic acid in the preparation of a drug for inhibiting tumor formation in chickens suffering from Marek's disease, characterized in that: When RA190 is used alone, its effective concentration at the cellular level is 0.01-100 μM; when RA190 and glycyrrhizic acid are used in combination, the molar concentration ratio of RA190: glycyrrhizic acid is 1:5-1:80.